In low-risk patients, we identified significantly higher numbers of CD68 +, PD-L1 + CD68 + and PD-L1 + FOXP3 + cells in the stroma relative to tumour (n = 9) (CD68 +: p = 0.0117, PD-L1 + CD68 +: p = 0.0039, PD-L1 + FOXP3 + CD4 + p = 0.0039, paired samples Wilcoxon signed-rank test, Figure 4A–H). This evidence concerns the gene CD68 and neoplasm.